thalidomide has been researched along with Germinoblastoma in 28 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The combination of pomalidomide (POM) and dexamethasone (DEX) was evaluated for relapsed/refractory primary central nervous system lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL) to determine the maximal tolerated dose (MTD) of POM as the primary objective, and overall response rate (ORR), progression-free survival (PFS), and safety profile as secondary objectives." | 9.27 | Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. ( Atherton, PJ; DeAngelis, LM; Grommes, C; Jaeckle, KA; Johnston, PB; Koenig, PA; O'Neill, B; Omuro, AMP; Pederson, LD; Pulido, J; Reeder, CB; Schiff, D; Tun, HW; Witzig, TE, 2018) |
| "This paper summarizes what is known about the mechanisms of action of lenalidomide, and recent clinical results in lymphoma and chronic lymphocytic leukemia." | 8.89 | Lenalidomide in lymphomas and chronic lymphocytic leukemia. ( Wiernik, PH, 2013) |
| " We investigated the immune stimulatory effects of lenalidomide, administrated to mice in doses, which provided comparable pharmacokinetics to human patients, on the potency of a novel fusion DNA lymphoma vaccine." | 7.80 | Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas. ( Bateman, S; Cha, SC; Chen, J; Kwak, LW; Lerman, B; Qin, H; Sakamaki, I; Surapaneni, S; Yi, Q, 2014) |
| "The current study suggests that thalidomide has limited single-agent activity in heavily pretreated patients with recurrent or refractory lymphoma." | 7.72 | Thalidomide for patients with recurrent lymphoma. ( Albitar, M; Cabanillas, F; Clemons, M; Dang, NH; Hagemeister, FB; McLaughlin, P; Pro, B; Rodriguez, MA; Romaguera, J; Samaniego, F; Younes, A, 2004) |
| "The case history of a fifteen year old patient with Thalidomide induced malformation who developed a lymphoma of high malignancy is presented." | 7.66 | [Coincidence of a thalidomide-induced malformation and a lymphoma of high malignancy (author's transl)]. ( Horwitz, A; Kosenow, W; Miller, A; Schmidt, CG, 1980) |
| "Pomalidomide (POM) is a novel immunomodulatory drug with anti-lymphoma activity." | 5.39 | Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models. ( Babusis, D; Copland, JA; Edenfield, B; Huang, P; Katz, J; Li, Z; Moghaddam, MF; Personett, D; Qiu, Y; Shirely, MA; Tang, Y; Tun, HW, 2013) |
| "Griseofulvin (GF) has similar chemical features as compared to ciclopirox olamine." | 5.37 | In vivo efficacy of griseofulvin against multiple myeloma. ( Alpmann, P; Blaum-Feder, S; Carson, D; Endo, T; Kim, Y; Krämer, S; Lu, D; Schmidt-Wolf, IG, 2011) |
| "Thalidomide has been associated with venous thrombotic events, as reported in the post-marketing surveillance reports by Celgene Corporation; as well as case reports in the literature." | 5.33 | Arterial thrombosis in four patients treated with thalidomide. ( Brown, K; Chanan-Khan, A; Hahn, T; McCarthy, PL; Paplham, P; Roy, H; Scarpace, SL; van Besien, K, 2005) |
| "The combination of pomalidomide (POM) and dexamethasone (DEX) was evaluated for relapsed/refractory primary central nervous system lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL) to determine the maximal tolerated dose (MTD) of POM as the primary objective, and overall response rate (ORR), progression-free survival (PFS), and safety profile as secondary objectives." | 5.27 | Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. ( Atherton, PJ; DeAngelis, LM; Grommes, C; Jaeckle, KA; Johnston, PB; Koenig, PA; O'Neill, B; Omuro, AMP; Pederson, LD; Pulido, J; Reeder, CB; Schiff, D; Tun, HW; Witzig, TE, 2018) |
| "This paper summarizes what is known about the mechanisms of action of lenalidomide, and recent clinical results in lymphoma and chronic lymphocytic leukemia." | 4.89 | Lenalidomide in lymphomas and chronic lymphocytic leukemia. ( Wiernik, PH, 2013) |
| " Thalidomide, lenalidomide and bortezomib have all been shown to be highly effective in multiple myeloma, and JAK2-inhibitors have entered phase II studies of patients with JAK2-positive primary myelofibrosis and related diseases." | 4.84 | [Novel medical treatment modalities in hematology]. ( Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A, 2008) |
| "We evaluated re-induction incorporating carfilzomib-thalidomide-dexamethasone (KTd) and autologous stem cell transplantation (ASCT) for newly diagnosed multiple myeloma (NDMM) refractory, or demonstrating a suboptimal response, to non-IMID bortezomib-based induction." | 4.31 | Response adaptive salvage with KTd and ASCT for functional high-risk multiple myeloma-The Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial. ( Horvath, N; Kalff, A; Kerridge, I; Khong, T; Lee, E; Morris, E; Quach, H; Reynolds, J; Spencer, A; Turner, R, 2023) |
| " We investigated the immune stimulatory effects of lenalidomide, administrated to mice in doses, which provided comparable pharmacokinetics to human patients, on the potency of a novel fusion DNA lymphoma vaccine." | 3.80 | Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas. ( Bateman, S; Cha, SC; Chen, J; Kwak, LW; Lerman, B; Qin, H; Sakamaki, I; Surapaneni, S; Yi, Q, 2014) |
| "Thalidomide and its analogs are effective agents in the treatment of multiple myeloma." | 3.76 | Thalidomide decreases gelatinase production by malignant B lymphoid cell lines through disruption of multiple integrin-mediated signaling pathways. ( Bladé, J; Cibeira, MT; Cid, MC; Corbera-Bellalta, M; Esparza, J; Izco, N; Lozano, E; Segarra, M; Vilardell, C, 2010) |
| "The current study suggests that thalidomide has limited single-agent activity in heavily pretreated patients with recurrent or refractory lymphoma." | 3.72 | Thalidomide for patients with recurrent lymphoma. ( Albitar, M; Cabanillas, F; Clemons, M; Dang, NH; Hagemeister, FB; McLaughlin, P; Pro, B; Rodriguez, MA; Romaguera, J; Samaniego, F; Younes, A, 2004) |
| "The case history of a fifteen year old patient with Thalidomide induced malformation who developed a lymphoma of high malignancy is presented." | 3.66 | [Coincidence of a thalidomide-induced malformation and a lymphoma of high malignancy (author's transl)]. ( Horwitz, A; Kosenow, W; Miller, A; Schmidt, CG, 1980) |
| "Pomalidomide (POM) is a novel immunomodulatory drug with anti-lymphoma activity." | 1.39 | Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models. ( Babusis, D; Copland, JA; Edenfield, B; Huang, P; Katz, J; Li, Z; Moghaddam, MF; Personett, D; Qiu, Y; Shirely, MA; Tang, Y; Tun, HW, 2013) |
| "Griseofulvin (GF) has similar chemical features as compared to ciclopirox olamine." | 1.37 | In vivo efficacy of griseofulvin against multiple myeloma. ( Alpmann, P; Blaum-Feder, S; Carson, D; Endo, T; Kim, Y; Krämer, S; Lu, D; Schmidt-Wolf, IG, 2011) |
| "Thalidomide has been associated with venous thrombotic events, as reported in the post-marketing surveillance reports by Celgene Corporation; as well as case reports in the literature." | 1.33 | Arterial thrombosis in four patients treated with thalidomide. ( Brown, K; Chanan-Khan, A; Hahn, T; McCarthy, PL; Paplham, P; Roy, H; Scarpace, SL; van Besien, K, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (10.71) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (35.71) | 29.6817 |
| 2010's | 14 (50.00) | 24.3611 |
| 2020's | 1 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Turner, R | 1 |
| Quach, H | 1 |
| Horvath, N | 1 |
| Kerridge, I | 1 |
| Lee, E | 1 |
| Morris, E | 1 |
| Kalff, A | 1 |
| Khong, T | 1 |
| Reynolds, J | 1 |
| Spencer, A | 1 |
| Tun, HW | 2 |
| Johnston, PB | 1 |
| DeAngelis, LM | 1 |
| Atherton, PJ | 1 |
| Pederson, LD | 1 |
| Koenig, PA | 1 |
| Reeder, CB | 1 |
| Omuro, AMP | 1 |
| Schiff, D | 1 |
| O'Neill, B | 1 |
| Pulido, J | 1 |
| Jaeckle, KA | 1 |
| Grommes, C | 1 |
| Witzig, TE | 1 |
| Sakamaki, I | 1 |
| Kwak, LW | 1 |
| Cha, SC | 1 |
| Yi, Q | 1 |
| Lerman, B | 1 |
| Chen, J | 1 |
| Surapaneni, S | 1 |
| Bateman, S | 1 |
| Qin, H | 1 |
| Xu, M | 1 |
| Hou, Y | 1 |
| Sheng, L | 1 |
| Peng, J | 1 |
| Li, Z | 1 |
| Qiu, Y | 1 |
| Personett, D | 1 |
| Huang, P | 1 |
| Edenfield, B | 1 |
| Katz, J | 1 |
| Babusis, D | 1 |
| Tang, Y | 1 |
| Shirely, MA | 1 |
| Moghaddam, MF | 1 |
| Copland, JA | 1 |
| Cheah, CY | 1 |
| Nastoupil, LJ | 1 |
| Neelapu, SS | 1 |
| Forbes, SG | 1 |
| Oki, Y | 1 |
| Fowler, NH | 1 |
| Grygorowicz, MA | 1 |
| Borycka, IS | 1 |
| Nowak, E | 1 |
| Paszkiewicz-Kozik, E | 1 |
| Rymkiewicz, G | 1 |
| Błachnio, K | 1 |
| Biernacka, M | 1 |
| Bujko, M | 1 |
| Walewski, J | 1 |
| Markowicz, S | 1 |
| Mehta-Shah, N | 1 |
| Horwitz, SM | 1 |
| Johnson, PW | 1 |
| Hasselbalch, HC | 1 |
| Birgens, H | 1 |
| Dufva, IH | 1 |
| Dalseg, AM | 1 |
| Brown, Pde N | 1 |
| Jensen, MK | 1 |
| Vangsted, A | 1 |
| Escoubet-Lozach, L | 1 |
| Lin, IL | 1 |
| Jensen-Pergakes, K | 1 |
| Brady, HA | 1 |
| Gandhi, AK | 1 |
| Schafer, PH | 1 |
| Muller, GW | 1 |
| Worland, PJ | 1 |
| Chan, KW | 1 |
| Verhelle, D | 1 |
| Segarra, M | 1 |
| Lozano, E | 1 |
| Corbera-Bellalta, M | 1 |
| Vilardell, C | 1 |
| Cibeira, MT | 1 |
| Esparza, J | 1 |
| Izco, N | 1 |
| Bladé, J | 1 |
| Cid, MC | 1 |
| Schmidt-Hieber, M | 1 |
| Dabrowski, R | 1 |
| Weimann, A | 1 |
| Aicher, B | 1 |
| Lohneis, P | 1 |
| Busse, A | 1 |
| Thiel, E | 1 |
| Blau, IW | 1 |
| Kim, Y | 1 |
| Alpmann, P | 1 |
| Blaum-Feder, S | 1 |
| Krämer, S | 1 |
| Endo, T | 1 |
| Lu, D | 1 |
| Carson, D | 1 |
| Schmidt-Wolf, IG | 1 |
| Agliano, A | 1 |
| Martin-Padura, I | 1 |
| Marighetti, P | 1 |
| Gregato, G | 1 |
| Calleri, A | 1 |
| Prior, C | 1 |
| Redrado, M | 1 |
| Calvo, A | 1 |
| Bertolini, F | 1 |
| Pan, B | 1 |
| Lentzsch, S | 1 |
| Ogura, M | 1 |
| Wiernik, PH | 1 |
| Chaudhry, V | 1 |
| Chaudhry, M | 1 |
| Crawford, TO | 1 |
| Simmons-O'Brien, E | 1 |
| Griffin, JW | 1 |
| ROE, FJ | 2 |
| MITCHLEY, BC | 1 |
| Pro, B | 2 |
| Younes, A | 2 |
| Albitar, M | 1 |
| Dang, NH | 1 |
| Samaniego, F | 1 |
| Romaguera, J | 1 |
| McLaughlin, P | 1 |
| Hagemeister, FB | 1 |
| Rodriguez, MA | 1 |
| Clemons, M | 1 |
| Cabanillas, F | 1 |
| Ribatti, D | 1 |
| Scavelli, C | 1 |
| Roccaro, AM | 1 |
| Crivellato, E | 1 |
| Nico, B | 1 |
| Vacca, A | 1 |
| Scarpace, SL | 1 |
| Hahn, T | 1 |
| Roy, H | 1 |
| Brown, K | 1 |
| Paplham, P | 1 |
| Chanan-Khan, A | 1 |
| van Besien, K | 1 |
| McCarthy, PL | 1 |
| Heinrich, B | 1 |
| Miller, A | 1 |
| Schmidt, CG | 1 |
| Horwitz, A | 1 |
| Kosenow, W | 1 |
| Hussein, MA | 1 |
| Walters, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Trial of Pomalidomide for Patients With Relapsed/Refractory Primary CNS Lymphoma and Primary Vitreoretinal Lymphoma[NCT01722305] | Phase 1 | 29 participants (Actual) | Interventional | 2013-04-08 | Completed | ||
| A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects[NCT01707407] | Phase 1 | 32 participants (Actual) | Interventional | 2012-09-01 | Completed | ||
| Study of Pomalidomide in Anal Cancer Precursors (SPACE): a Phase 2 Study of Immunomodulation in People With Persistent HPV-associated High Grade Squamous Intraepithelial Lesions[NCT03113942] | Phase 2 | 26 participants (Actual) | Interventional | 2017-06-14 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for thalidomide and Germinoblastoma
| Article | Year |
|---|---|
Therapeutic effects of thalidomide in hematologic disorders: a review.
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Graft vs Host Disease; Hematologic Neoplasms; Hum | 2013 |
New targets for lymphoma treatment.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Clinical Trials, Phase II as Topic; Enzyme | 2008 |
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antib | 2008 |
The application and biology of immunomodulatory drugs (IMiDs) in cancer.
Topics: Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid | 2012 |
Lenalidomide in lymphomas and chronic lymphocytic leukemia.
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Disease-Free Survival; Humans; Lenalidomide; Leuk | 2013 |
New molecular targets for treatment of lymphoma.
Topics: Antineoplastic Agents; Cell Proliferation; Cell Survival; Enzyme Inhibitors; Humans; Lymphoma; Medic | 2004 |
Hematopoietic cancer and angiogenesis.
Topics: Angiogenesis Inhibitors; Cell Proliferation; Disease Progression; Endothelium, Vascular; Hematologic | 2004 |
Research on thalidomide in solid tumors, hematologic malignancies, and supportive care.
Topics: Antioxidants; DNA Damage; Humans; Immunosuppressive Agents; Leukemia; Lymphoma; Neoplasms; Neovascul | 2000 |
3 trials available for thalidomide and Germinoblastoma
| Article | Year |
|---|---|
Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neopla | 2018 |
Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neopla | 2018 |
Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neopla | 2018 |
Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neopla | 2018 |
Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Female | 2015 |
[Current development of new drugs in malignant lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bendamustine Hydro | 2012 |
17 other studies available for thalidomide and Germinoblastoma
| Article | Year |
|---|---|
Response adaptive salvage with KTd and ASCT for functional high-risk multiple myeloma-The Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell T | 2023 |
Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas.
Topics: Animals; Antibodies; Antibody Specificity; Antineoplastic Agents; Cancer Vaccines; Disease Models, A | 2014 |
Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models.
Topics: Angiogenesis Inhibitors; Animals; Cells, Cultured; Central Nervous System Neoplasms; Disease Models, | 2013 |
Lenalidomide potentiates CD4
Topics: Adult; Aged; B-Lymphocytes; Blood Donors; CD4 Antigens; Cell Proliferation; Cells, Cultured; Female; | 2017 |
Lenalidomide in Adult T-Cell Leukemia/Lymphoma.
Topics: Adult; Angiogenesis Inhibitors; Humans; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Lymphoma; Tha | 2016 |
Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chromatin; Cyclin-Dependent Kinase Inhibitor p21; Gene Expr | 2009 |
Thalidomide decreases gelatinase production by malignant B lymphoid cell lines through disruption of multiple integrin-mediated signaling pathways.
Topics: B-Lymphocytes; Blotting, Western; Cell Adhesion; Cell Movement; Cells, Cultured; Gelatinases; Humans | 2010 |
In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bor | 2012 |
In vivo efficacy of griseofulvin against multiple myeloma.
Topics: Animals; Antifungal Agents; Antineoplastic Agents; Apoptosis; beta Catenin; Cell Line, Tumor; Ciclop | 2011 |
Therapeutic effect of lenalidomide in a novel xenograft mouse model of human blastic NK cell lymphoma/blastic plasmacytoid dendritic cell neoplasm.
Topics: Animals; Antineoplastic Agents; Dendritic Cells; Disease Models, Animal; Drug Evaluation, Preclinica | 2011 |
Toxic neuropathy in patients with pre-existing neuropathy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Dose-Respo | 2003 |
THALIDOMIDE AND NEOPLASIA.
Topics: Carcinogens; Carcinoma, Hepatocellular; Liver Neoplasms; Lymphoma; Mice; Neoplasms; Neoplasms, Exper | 1963 |
Thalidomide for patients with recurrent lymphoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Cytokines; Humans; Lymphoma; Middle Aged; Recurrence; Salvage | 2004 |
Arterial thrombosis in four patients treated with thalidomide.
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Drug Therapy, Combination; Female; Humans; Intracranial | 2005 |
[Therapeutic outcomes in systemic lymphatic diseases and plasmacytoma. New hope for palliative patients].
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lymphoma; M | 2005 |
[Coincidence of a thalidomide-induced malformation and a lymphoma of high malignancy (author's transl)].
Topics: Abnormalities, Drug-Induced; Adolescent; Female; Humans; Lymphoma; Mediastinal Neoplasms; Pathology; | 1980 |
Sensitivity of newborn mice to carcinogenic agents.
Topics: Adenocarcinoma; Adenoma; Animals; Animals, Newborn; Benz(a)Anthracenes; Carcinogens; Carcinoma, Hepa | 1968 |